Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00153868 · ClinicalTrials.gov registry record · Phase 4
A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer
A Phase 4 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
NCT00153868: Completed Phase 4 study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT00153868 is a Phase 4 study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 43 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00153868, a Phase 4 study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
Study Summary
This is a web-based pilot study to evaluate the association between the treatment of anemia with darbepoetin alfa (aranesp) and the clinical benefits in symptom palliation, improved functional status and quality of life in patients with cancer. The feasibility of web-based assessments and data capture will be evaluated.
Interventions
- BIOLOGICAL darbepoetin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2003-10 |
| Est. Completion | 2007-08-17 |
| Phase | Phase 4 |
What the finished NCT00153868 record still lists
NCT00153868 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which darbepoetin alfa is the first listed.
NCT00153868 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00153868 about?
NCT00153868 is a clinical study titled "A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer". This is a web-based pilot study to evaluate the association between the treatment of anemia with darbepoetin alfa (aranesp) and the clinical benefits in symptom palliation, improved functional status and quality of life in patients with cancer. The feasibility of web-based assessments and data captu...
What is the current status of trial NCT00153868?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2003-10. Estimated completion is 2007-08-17.
What interventions are being tested in trial NCT00153868?
The interventions under investigation include: darbepoetin alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00153868?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00153868's enrollment target sits among peer trials
43 1371st of 2000 higher than 621 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia